Engineers Gate Manager LP Reduces Stock Position in Harmony Biosciences Holdings, Inc. $HRMY

Posted by Brian Himes on Sep 13th, 2026

Engineers Gate Manager LP lessened its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) by 31.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 110,797 shares of the company’s stock after selling 50,828 shares during the period. Engineers Gate Manager LP’s holdings in Harmony Biosciences were worth $4,034,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. EverSource Wealth Advisors LLC raised its stake in shares of Harmony Biosciences by 589.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock valued at $28,000 after acquiring an additional 643 shares during the last quarter. Leonteq Securities AG purchased a new stake in shares of Harmony Biosciences during the fourth quarter worth about $30,000. Allworth Financial LP grew its stake in shares of Harmony Biosciences by 286.7% in the fourth quarter. Allworth Financial LP now owns 812 shares of the company’s stock worth $30,000 after purchasing an additional 602 shares during the last quarter. Nykredit A S bought a new stake in shares of Harmony Biosciences in the second quarter worth about $33,000. Finally, National Bank of Canada FI purchased a new position in Harmony Biosciences during the 3rd quarter valued at about $40,000. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Trading Up 1.0%

Shares of HRMY opened at $41.52 on Friday. Harmony Biosciences Holdings, Inc. has a 1-year low of $25.52 and a 1-year high of $43.49. The company has a current ratio of 3.48, a quick ratio of 3.45 and a debt-to-equity ratio of 0.13. The firm’s 50-day moving average price is $38.12 and its 200-day moving average price is $33.25. The firm has a market capitalization of $2.42 billion, a price-to-earnings ratio of 13.48, a PEG ratio of 0.38 and a beta of 0.93.

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $1.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.96 by $0.32. Harmony Biosciences had a net margin of 18.88% and a return on equity of 20.06%. The company had revenue of $261.28 million during the quarter, compared to the consensus estimate of $250.77 million. During the same period in the prior year, the firm earned $0.92 earnings per share. Harmony Biosciences’s revenue was up 30.3% on a year-over-year basis. Sell-side analysts anticipate that Harmony Biosciences Holdings, Inc. will post 3.77 EPS for the current year.

Insider Buying and Selling at Harmony Biosciences

In other Harmony Biosciences news, insider Kumar Budur sold 28,454 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $42.96, for a total transaction of $1,222,383.84. Following the transaction, the insider owned 13,115 shares in the company, valued at approximately $563,420.40. This represents a 68.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 11.00% of the company’s stock.

Wall Street Analysts Forecast Growth

HRMY has been the subject of a number of recent analyst reports. UBS Group reaffirmed a “neutral” rating and set a $37.00 price target on shares of Harmony Biosciences in a research report on Wednesday, August 5th. Truist Financial lifted their price objective on Harmony Biosciences from $29.00 to $34.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Mizuho boosted their target price on Harmony Biosciences from $50.00 to $51.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of Harmony Biosciences in a research note on Thursday, July 16th. Finally, Weiss Ratings upgraded Harmony Biosciences from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, August 17th. Five investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $47.11.

View Our Latest Analysis on HRMY

Harmony Biosciences Profile

(Free Report)

Harmony Biosciences Holdings, Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological disorders. The company was founded in 2017 and is headquartered in Plymouth Meeting, Pennsylvania, with an emphasis on conditions that are often underserved by traditional pharmaceutical research.

Harmony’s principal product is WAKIX (pitolisant), a first-in-class histamine H3 receptor antagonist/inverse agonist approved by the U.S.